Background. Obesity, type 2 diabetes (T2D), dyslipidemia, arterial hypertension as well as hepatic
Data on liver and cardiometabolic events such as cirrhosis and its complications, hepatocellular carcinoma, coronary artery disease, arterial hypertension, impaired fasting glucose (IFG)/type 2 diabetes (T2D) and dyslipidemia, were collected over time.
Results. The mean age of the whole cohort was 46 ± 12 years and 114/188 (61%) patients were males. HS was found in 82/188 (43.6%) patients and most of them were infected by HCV genotype 3a. The prevalence of obesity, IFG/T2D, dyslipidemia and arterial hypertension was 4.3%, 6.9%, 37 .2% and 5.9%, and was similarly distributed among patients with and without HS. Cirrhosis was histologically diagnosed in 18/188 (9.6%) patients. After a median follow-up of 11 years (range 3-21), the cumulative incidence of cardiovascular events, IFG/T2D and dyslipidemia was higher in CHC-LTRs who had HS at baseline compared to those without HS (1.2%, 2.3% and 3.0% vs 0.4%; 0.8% and 2.5%, respectively). At multivariable Cox regression analysis, HS was significantly associated to the development of cardiovascular events and IFG/T2D (HR=5.2, 95%CI=1.3-20.7, p=0.019 and HR=2.6, 95%CI=1.1-6.2, p=0.027, respectively).
Conclusions.
In CHC-LTRs, HS at baseline may predispose to the development of cardiovascular events and T2D during follow-up emphasizing the importance of an accurate counseling in order to prevent extra-hepatic complications. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 15 In this context, the aim of this study was to define the main baseline metabolic predictors of clinical outcomes in a monocentric cohort of CHC-LTRs who underwent liver biopsy at the time of HCV antiviral therapy. Antiviral therapy duration was 48 weeks or less according to specific guidelines. 5 The beginning of follow-up for each patient started at the initiation of antiviral therapy while the end coincided with the last medical examination available (at least three years after the end of treatment). Long-term were collected from medical records prior to treatment initiation and at the last available follow-up visit. Liver biopsies were analyzed at baseline by an expert pathologist. Hepatic fibrosis and inflammation were scored according to Ishak classification. 16 Steatosis was defined as absent or significant if the percentage of fat into the hepatocytes was less than 5% or ≥ 5%, respectively.
Materials and Methods

Patients
All patients gave their consent for including their personal data in the database. The study was approved by the ethics committee of the University Hospital Città della Salute e della Scienza of
Turin and was in accordance with the Helsinki Declaration.
Metabolic cofactors definition
Metabolic cofactors considered in this study were: overweight/obesity (BMI ≥ 24. and HS at biopsy (≥ 5%).
Follow up and clinical outcomes
All the patients were followed-up for at least 3 years (median FU period 10 years): every 6 months after the end of antiviral treatment for the first 2 years and every 24 months, subsequently. Cirrhotic patients were examined every 6 months. The liver-related events occurred during FU and considered for the analysis were collected from the outpatients' registries and were: the development of cirrhosis and its complications (ascites, bleeding varices, hepatic encephalopathy and HCC). The diagnosis of HCC was done using imaging techniques. The cardiovascular events considered in the analysis included acute myocardial infarction and stroke. 
Results
Clinical features of the study population at baseline
A total of 188 CHC patients (114 male, 61%) were followed-up for 3 to 21 years (mean 11 years).
Most of the patients (93%) were treated with the combination of pegylated IFN and RBV while the others received the IFN monotherapy. Baseline clinical, biochemical and histological characteristics of the study cohort, according to the presence or absence of HS, are reported in Table 1) .
Follow-up analysis
After 20 years of follow-up, one CHC patient had a recurrence of HCV infection. Of the 6 deaths occurred, 2 LTRs died for liver-related events, 3 for cardiovascular events and 1 for colorectal cancer ( Table 2 ). The cumulative incidence of mortality was similar in LTRs who had HS at biopsy compared to those who did not have HS (Table 2) .
Liver-related morbidity
Liver-related events occurred in 5 LTRs with a cumulative incidence of 0.3%. One subject developed cirrhosis, 1 with pre-existent cirrhosis at baseline developed its complications (hepatic decompensation), 3 subjects developed HCC (2 on cirrhotic liver and 1 on non-cirrhotic liver with steatosis). Baseline HS did not impact on the development of liver-related events during follow-up (Table 2) . Conversely, CHC-LTRs who had severe fibrosis at baseline showed a higher cumulative incidence of liver related outcomes compared to those with mild/moderate fibrosis (0.9% vs 0.1%, p<0.001) (Supplementary Table 2 ). After multivariable Cox regression analysis adjusted for age, sex, BMI and HCV genotypes, severe fibrosis was the only baseline predictor of liver-related outcomes with a hazard ratio (HR) of 11 (95% CI=1.5-87.9, p=0.025, data not shown). Overall, cardiovascular events occurred in 14 LTRs and the cumulative incidence was significantly higher in those who had HS at liver biopsy compared to those without HS (1.2% vs 0.4%, p=0.011) ( Table 2) . At univariate Cox regression analysis, IFG/T2D, dyslipidemia and HS showed a higher probability to develop cardiovascular events (Figure 2 A-C) . After multivariable Cox regression analysis, the only metabolic cofactor significantly associated to a higher risk of developing cardiovascular events was IFG/T2D (HR=5.2, 95% CI=1.3-20.7, p=0.019) ( Table 3 ).
Cardiometabolic-related morbidity
Arterial hypertension occurred in 24 LTRs with a similar cumulative incidence in both patients with and without HS at liver biopsy (1.4% vs 1.3%, p=0.610) ( Figure 2D ). At univariate Cox regression analysis, no metabolic cofactors were significantly associated to the development of arterial hypertension over time, and multivariable analysis confirmed this result.
Overall, the cumulative incidence of overweight/obesity, IFG/T2D and dyslipidemia was 1.2%, 1.5% and 2.8%, respectively (Table 2 ). Specifically, the cumulative incidence of IFG/T2D and dyslipidemia was significantly higher in LTRs who had HS at liver biopsy compared to those who did not have HS (2.3% vs 0.8%, p=0.005 and 3.0% vs 2.5%, p=0.010, respectively), while the cumulative incidence of overweight/obesity was similar among the two groups.
At univariate Cox regression analysis, older age, dyslipidemia and HS were significantly associated to the development of IFG/T2D. After multivariable analysis, the only baseline metabolic cofactor associated to the development of IFG/T2D was HS (HR=2.6, 95% CI=1.1-6.2, p=0.027) ( Table 4) .
Concerning the other metabolic outcomes, older age increased the risk of developing dyslipidemia during follow-up (HR=1.0, 95% CI=1.0-1.1, p=0.005) (Supplementary Table 3 ) while no baseline cofactors increased the risk of overweight/obesity over time.
Discussion
In this study, on 188 CHC LTRs to IFN and RBV therapy, we assessed the impact of metabolic cofactors (HS, overweight/obesity, T2D, dyslipidemia and arterial hypertension) on the Particularly, it is well known that HS may be considered as a marker of metabolic dysfunction predisposing to the development of clinical events even after a long time from HCV eradication. On the other side, CHC infection has been associated with a poor prognosis affecting both liver-and cardio-metabolic-related outcomes. 17 The median duration of FU was 11 years (range 3-21), one of the longer. Concerning virological and histological characteristics, our population slightly differs from another cohort of 150 Italian CHC-LTRs. In fact, in the former, the prevalence of HCV genotype 3a was higher compared to that reported by Morisco (17.6% vs 3.3%). Similarly the prevalence of cirrhosis was higher in our cohort compared to that reported in the other cohort (9.6% vs 1.3%).
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At the time of baseline screening for antiviral therapy, HS was found at liver biopsy in 82 LTRs with a prevalence of 43.6%. This data was in agreement with several studies indicating that, in the setting of HCV infection, the prevalence of HS may range from 42% to 73%. [19] [20] It is well known that HS can be induced directly by HCV genotype 3a (viral steatosis) or indirectly, through the development of IR, by HCV-genotype 1 (metabolic steatosis). [21] [22] [23] [24] [25] [26] Particularly, HCV genotypes 1 and 4 infection is associated to the development of IR regardless of the presence of steatosis.
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Recently, Lerat et al. demonstrated that in HCV transgenic mice, the development of IR and glucose intolerance are supported by HCV per se through the expression of viral proteins in the hepatocytes which negatively act on the glucose uptake by the liver through the down-regulation of Glut2 and IRS-2 expression via SOCS3-dependent mechanisms. 28 Unfortunately, in our population we did not have data on homeostasis model of assessment (HOMA)-IR, but we showed that in HCV patients infected with HCV genotype non-3, baseline BMI was significantly higher compared to those infected with HCV genotype 3a indicating that in the first group, steatosis was mainly driven by metabolic rather than viral derangements. Conversely, 67% of HCV genotype 3a infected patients had HS at biopsy, probably driven by viral infection. The cumulative incidence of IGF/T2D in our population is 1.5%, the same reported by Giordanino et al. 30 In their study, the authors stated that HCV eradication did not significantly reduce the risk of IFG/T2D during 8 years FU and that the incidence of T2D was similar in LTRs compared to nonresponders at IFN or PegIFN plus RBV treatment. 30 In another study, Metha et al. demonstrated that among 1084 non-diabetic subjects at baseline, HCV infection was associated with an elevated risk of T2D development over 9 years FU. 31 The incidence of cardiovascular events was 3-fold higher in CHC-LTRs who had HS at baseline compared to those without HS, and this data is comparable to that reported in the Italian population. 32 The link between HCV infection and CAD is supported by the fact that HCV is able to interfere with both glucose and lipid metabolism, leading to the development of IR, HS and T2D, which are directly associated to atherosclerosis development. 33 Furthermore, HCV increases cardiovascular risk by inducing a systemic inflammatory status and oxidative stress. 33 Specifically, HCV infection promotes inflammation increasing pro-inflammatory cytokines levels such as interleukin (IL)-6, tumor necrosis factor alpha (TNF-a), C-reactive protein (CRP) and fibrinogen which in turn are associated with increased risk of CAD. [34] [35] According to previous data, we confirm that hepatic fibrosis is the main risk factor for the development of hepatic complications. [36] [37] The incidence of HCC in our population was very low (0.2%) and similar between CHC-LTRs who had HS at baseline and those who did not have HS.
The association between HS and fibrosis in the setting of HCV infection is controversial: while in the majority of the studies a robust association has been reported, 38-40 some authors did not find any relationship. 41 Our study has some limitations. The first is the lack of a second liver biopsy making difficult the longitudinal comparison of the degree of hepatic fibrosis and steatosis. Nevertheless, from an 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55 Page 10 of 23 ethical point of view, in the clinical setting, it would be difficult to perform a second liver biopsy for histological revaluation. The second limitation is the retrospective design of the study making difficult to find clinical data from old medical records. Furthermore, during the last 30 years, all consultations has been recorded in both a paper archive and a digital databank. However, the potential heterogeneity arising from this, is limited by the fact that in our unit all authors followed international guidelines. Finally, we are aware that the lack of data on alcohol consumption in our cohort may represent another important limitation. However, all patients stopped drinking at the time of HCV diagnosis and during antiviral treatment.
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Metabolic-related outcomes
